BioAtla/BCAB

$2.41

6.63%
-
1D1W1MYTD1YMAX

About BioAtla

BioAtla, Inc. is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of solid tumor cancer. The Company’s product candidates include BA3011 (Mecbotamab vedotin), BA3021 (Ozuriftabmab vedotin), BA3071 and BA3182. Its lead product candidate, BA3011, is a conditionally active biologics (CAB) antibody-drug conjugates (ADC) that targets AXL, which is a protein kinase receptor. BA3021 is developing a CAB antibody drug conjugate directed against a receptor tyrosine kinase such as orphan receptor 2 (ROR2). BA3071 is a CAB anti-CTLA-4 antibody that is being developed as a therapeutic for multiple solid tumor indications, including renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder and gastric cancer, and cervical cancer. BA3182 is designed with an EpCAM binding domain and a CD3 binding domain, both binding domains with CAB activity (Dual-CAB), for the treatment of advanced adenocarcinoma.
Ticker
BCAB
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Jay Short
Employees
66
Headquarters
San diego, United States

BioAtla Metrics

BasicAdvanced
$108.33M
Market cap
-
P/E ratio
-$2.66
EPS
-
Beta
-
Dividend rate

What the Analysts think about BioAtla

Analyst Ratings

Majority rating from 5 analysts.
Buy

Price Targets

Average projection from 4 analysts.
408.3% upside
High $14.00
Low $10.00
$2.41
Current price
$12.25
Average price target

BioAtla Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$0
-
Net income
$-33.3M
-6.72%
Profit margin
0%
-

BioAtla Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 12.5%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.63
-$0.58
-$0.75
-$0.70
-
Expected
-$0.70
-$0.63
-$0.64
-$0.80
-$0.79
Surprise
-9.67%
-7.64%
17.19%
-12.5%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell BioAtla stock

Buy or sell BioAtla stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing